EUVIMEDEUVIMED entdecken
Crossref

Early WEE1 inhibition prevents senescence-like epigenetic reprogramming of pioneer TMZ-resistant cells and synergizes with temozolomide in MYC-high glioblastoma

Yilin Wu, Yuzhou Chang, Xiaoyang Qin, Jialin Jin, Bo Pang, Ran Yin, Yun Liu, Hao Yan, Yuanhao Chang, Yang Chu, Guixia Li, Xiaohui Ma und 2 weitere

Cancer Letters · 2026-12 · 662 · 218913

DOI: 10.1016/j.canlet.2026.218913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Yilin Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Cell Cycle Proteins, Proto-Oncogene Proteins c-myc. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Major Science and Technology Projects of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In proliferative glioblastoma, a subset of tumor cells survives early temozolomide (TMZ) exposure and drives eventual-resistance, yet the underlying mechanism remains unclear. We found that MYC target activation was associated with attenuated TMZ survival benefit in CGGA cohorts. In patient-derived MYC-high glioma cells, TMZ increased apoptosis but left a larger residual viable population due to enhanced proliferation; we defined these surviving cells as pioneer resistant (P-R) cells, which exhibited reduced TMZ sensitivity and a competitive survival advantage. Mechanistically, P-R cells adopted a senescence-like state via two coordinated arms of chromatin remodeling. On one hand, H3K27ac-dependent super-enhancers were gained at senescence-associated secretory genes; the CBP/p300 inhibitor A485 reverted the senescence-like state and restored TMZ cytotoxicity; On another hand, chromatin closed, reducing MYC occupancy at cell-cycle genes despite unchanged MYC protein, and suppressed nascent transcription and m6A modification, accompanied by cell-cycle arrest in some P-R cells. Furthermore, time-course analysis revealed that chromatin closure at cell-cycle genes is likely a temporally ordered epigenetic remodeling process, initiated by DNA damage-associated G2/M arrest mediated by WEE1 activation, followed by γH2AX-mediated recruitment of SUV39H1, which deposits H3K9me3 at MYC-bound loci to close chromatin. Functionally, early, but not delayed, inhibition of WEE1 with the novel brain-penetrant inhibitor TSL2304 blocked senescence-like epigenetic reprogramming, synergized with TMZ in vitro, and significantly prolonged survival in an orthotopic glioblastoma model. Together, these findings reveal a temporally ordered epigenetic remodeling in MYC-high glioblastoma that promotes survival after early TMZ exposure, and identify early WEE1 inhibition as a strategy to synergize with TMZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaCell Cycle ProteinsProto-Oncogene Proteins c-mycEpigenesis, GeneticDrug Resistance, NeoplasmNuclear ProteinsBrain NeoplasmsHumansCellular SenescenceProtein-Tyrosine KinasesCell Line, TumorAnimalsDrug SynergismAntineoplastic Agents, AlkylatingCell ProliferationApoptosisGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysChromatin Assembly and Disassembly

Stichwörter der Autor:innen

Epigenetic reprogrammingGliomaMYCWEE1 inhibitorm(6)A modification

Substanzen

TemozolomideWEE1 protein, humanCell Cycle ProteinsProto-Oncogene Proteins c-mycProtein-Tyrosine KinasesMYC protein, humanNuclear ProteinsAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical Uni…
  • Pharmacology & Toxicology Department of R&D Center, Tasly Pharmaceuticals Co., Ltd., Tianjin, 300410, China.
  • Beijing Key Laboratory of Drug Innovation for Neuro-Oncology, Beijing, China; Pharmacology & Toxicology Department of R&D Center, Tasly Pharmaceuticals Co., Ltd., Tianjin, 300410, China; Beijing Engineering Research Cen…
  • Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Drug Innovation for Neuro-Oncology, Beijing, Ch…

Förderung

  • National Major Science and Technology Projects of China
  • National Natural Science Foundation of China

Zitieren

APA

Wu, Y., Chang, Y., Qin, X., Jin, J., Pang, B., Yin, R., Liu, Y., Yan, H., Chang, Y., Chu, Y., Li, G., Ma, X., Wang, Y., & Chai, R. (2026). Early WEE1 inhibition prevents senescence-like epigenetic reprogramming of pioneer TMZ-resistant cells and synergizes with temozolomide in MYC-high glioblastoma. Cancer Letters, 662, 218913. https://doi.org/10.1016/j.canlet.2026.218913

Vancouver

Wu Y, Chang Y, Qin X, Jin J, Pang B, Yin R, et al. Early WEE1 inhibition prevents senescence-like epigenetic reprogramming of pioneer TMZ-resistant cells and synergizes with temozolomide in MYC-high glioblastoma. Cancer Letters. 2026;662:218913. doi:10.1016/j.canlet.2026.218913

BibTeX
@article{Wu2026,
  author = {Wu, Yilin and Chang, Yuzhou and Qin, Xiaoyang and Jin, Jialin and Pang, Bo and Yin, Ran and Liu, Yun and Yan, Hao and Chang, Yuanhao and Chu, Yang and Li, Guixia and Ma, Xiaohui and Wang, Yongzhi and Chai, Ruichao},
  title = {Early WEE1 inhibition prevents senescence-like epigenetic reprogramming of pioneer TMZ-resistant cells and synergizes with temozolomide in MYC-high glioblastoma},
  journal = {Cancer Letters},
  year = {2026},
  volume = {662},
  pages = {218913},
  doi = {10.1016/j.canlet.2026.218913}
}
Kostenlos starten →